---
layout: post
title: "葛兰基金大涨！CXO成反弹先锋 机构称板块估值底已现"
date: 2022-02-15 15:37:55 +0800
categories: emnews
tags: 东财滚动新闻
---
> 身处风口浪尖的葛兰和中欧基金终于得以喘息。截至15日收盘，重仓CXO的中欧医疗健康混合A和中欧医药创新股票A估算涨幅分别达5.2%、6.43%。（财联社）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK0899" data-code="BK0899|90|1" data-code2="BK0899|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK0899&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK0899_0" data-code="K BK0899|90|1" data-code2="K BK0899|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>身处风口浪尖的葛兰和<span id="Info.3213"><a href="http://fund.eastmoney.com/company/80065113.html" class="infokey">中欧基金</a></span>终于得以喘息。<br /></p><p>截至15日收盘，重仓CXO的中欧医疗健康混合A和中欧医药创<span id="Info.3309"><a href="http://data.eastmoney.com/xg/xg/default.html" class="infokey">新股</a></span>票A估算涨幅分别达5.2%、6.43%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25623237354792488375_w3255h2266.jpg" alt="image" width="580" emheight="404" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>从盘面上看，CXO板块延续昨日反弹态势。其中，A股<span id="stock_0.301201"><a href="http://quote.eastmoney.com/unify/r/0.301201" class="keytip" data-code="0,301201">诚达药业</a></span><span id="quote_0.301201"></span>20cm涨停，<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>涨停，<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>盘中涨超17%，<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>涨超10%，<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>涨超9%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25348751484559324640_w630h399.jpg" alt="image" width="580" emheight="367" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>昨日，<span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>发布<span id="Info.314"><a href="http://data.eastmoney.com/report/" class="infokey">研究报告</a></span>，旗帜鲜明地指出，<strong>CXO龙头PEG已回归至1左右，板块处于估值底部。</strong>对于<span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>被列入UVL一事，该机构也持乐观态度，认为<strong>对公司及行业影响极为有限，且有望未来数月内移出清单。</strong></p><p><strong>CXO龙头PEG均值0.93 估值底部显现</strong></p><p><span web="1" href="http://quote.eastmoney.com/unify/r/1.601555" class="em_stock_key_common" data-code="1,601555">东吴证券</span><span id="Info.3224"><a href="http://data.eastmoney.com/invest/invest/default.html" class="infokey">分析师</a></span>朱国广认为，CXO板块已进入较低估值分位。其报告显示，CXO估值高点为2021年2月出现的139倍；最低值则是在2019年1月的42倍，截至2022年2 月11日，板块市盈率为61倍，已经低于71倍的历史中位数，处于26%的历史估值分位。2022年国内主流CXO公司平均市盈率为41倍，PEG均值0.93。</p><center><img src="https://dfscdn.dfcfw.com/download/D25353587967996292439_w890h446.jpg" alt="image" width="580" emheight="291" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25465421140103771499_w1060h221.jpg" alt="image" width="580" emheight="121" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><center><img src="https://dfscdn.dfcfw.com/download/D24699410823755659090_w1060h182.jpg" alt="image" width="580" emheight="100" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>在<span web="1" href="http://quote.eastmoney.com/unify/r/1.601555" class="em_stock_key_common" data-code="1,601555">东吴证券</span>看来，中国CXO公司被列入美国实体清单可能性较小，且企业<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>能见度从未改变，行业景气度不变。</p><p>报告中表示，<strong>国内龙CXO公司已与美国龙头药企合作多年，且承接大批新冠药物订单，若美国药企更换CXO服务商要面临高成本、高风险的局面。</strong>另外，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02269" class="em_stock_key_common" data-code="116,02269">药明生物</span>被列入UVL对公司及行业影响也极为有限，且有望未来数月内移出清单。</p><p><strong><span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>新冠口服药获批利好CXO</strong></p><p>2月11日，国家药监局通过应急审评审批，附条件批准<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠口服药奈玛特韦片/利托那韦片组合包装(Paxlovid)进口注册。</p><p>消息一出，随即引发市场关注，2月14日开盘，与<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠口服药相关CXO及原料药上市企业即出现大涨，其中科创板企业<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="stock_0.300261"><a href="http://quote.eastmoney.com/unify/r/0.300261" class="keytip" data-code="0,300261">雅本化学</a></span><span id="quote_0.300261"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.301201" class="em_stock_key_common" data-code="0,301201">诚达药业</span>涨停(20%)，<span id="stock_1.600668"><a href="http://quote.eastmoney.com/unify/r/1.600668" class="keytip" data-code="1,600668">尖峰集团</a></span><span id="quote_1.600668"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>涨停(10%)。</p><p><span id="stock_1.601066"><a href="http://quote.eastmoney.com/unify/r/1.601066" class="keytip" data-code="1,601066">中信建投</a></span><span id="quote_1.601066"></span><span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>认为，<strong>新冠口服药物商业化潜力巨大，利好小分子CDMO龙头。</strong>辉瑞公司预计2022年Paxlovid供应1.2亿人份，对应上游供应链潜力巨大，有利于中国优秀的小分子CDMO龙头企业。通过跟踪全球创新药投融资情况以及MNC研发费用情况，看到医药创新持续加码，CXO行业业绩具有持续性。</p><p><span id="stock_0.000166"><a href="http://quote.eastmoney.com/unify/r/0.000166" class="keytip" data-code="0,000166">申万宏源</a></span><span id="quote_0.000166"></span>陈烨远认为，随着国内紧急批准辉瑞新冠小分子口服药物，直接影响国内相关CXO公司或将会持续受益于相关订单的获取，从而推动国内CXO公司进一步加入全球创新药产业链。</p><p class="em_media">（文章来源：财联社）</p>

<http://finance.eastmoney.com/news/1345,202202152277167395.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)